4 ms·

Take from the rich, give to the poor.

QML 10y ago
Not all commercial entities are rich. If you were a scientist who found a novel application of CRISPR and wanted to develop a product and bring it to market, you'd be effectively screwed.
- hprotagonist 10y ago
  Well, you'd develop a proof of concept and angle to be acquihired by Editas. I don't know that that counts as "screwed".
  - QML 10y ago
    Acquihired implies you being acquired for your talent, but then what happens to your idea? Editas could just scrap it.
    - adventured 10y ago
      Editas and Broad only control the US market. It's extremely unlikely Broad will acquire such a strong position in Europe or Asia (in fact it's practically guaranteed they will not). If you had such a stellar therapy, and you couldn't get it past Editas, you'd go to Europe and partner with any number of a dozen other entities there that would be guaranteed to be interested (such as Novartis, which owns part of NTLA).
- vinceguidry 10y ago
  Just wait for the patent to expire. Or, don't wait, build out your product, and release it the second the patent expires. If it's a good enough idea, you'll be able to find investors willing to bridge the time gap.
stephancoral 10y ago
That's generally how a functioning and equitable society works yes
kobeya 10y ago
Good luck getting funding for a Crispr startup.
- jghn 10y ago
  I'd imagine that they'd be willing to license the technology to a startup for a stake in the company or something like that.
  - dekhn 10y ago
    The bar is pretty high for anybody who wants to make a product based on in-human CRISPR: https://www.broadinstitute.org/partnerships/office-strategic-alliances-and-partnering/information-about-licensing-crispr-genome-edi https://www.broadinstitute.org/partnerships/office-strategic... In short, if you want to sell a product, Editas gets right of first refusal to license from Broad, and only if they refuse would the startup be able to proceed to license. If you just want to use CRISPR for in house research, you have to license it; no idea if the fees are prohibitive.

QML 10y ago

Not all commercial entities are rich. If you were a scientist who found a novel application of CRISPR and wanted to develop a product and bring it to market, you'd be effectively screwed.

hprotagonist 10y ago
Well, you'd develop a proof of concept and angle to be acquihired by Editas. I don't know that that counts as "screwed".
- QML 10y ago
  Acquihired implies you being acquired for your talent, but then what happens to your idea? Editas could just scrap it.
  - adventured 10y ago
    Editas and Broad only control the US market. It's extremely unlikely Broad will acquire such a strong position in Europe or Asia (in fact it's practically guaranteed they will not). If you had such a stellar therapy, and you couldn't get it past Editas, you'd go to Europe and partner with any number of a dozen other entities there that would be guaranteed to be interested (such as Novartis, which owns part of NTLA).
vinceguidry 10y ago
Just wait for the patent to expire. Or, don't wait, build out your product, and release it the second the patent expires. If it's a good enough idea, you'll be able to find investors willing to bridge the time gap.

stephancoral 10y ago

That's generally how a functioning and equitable society works yes

kobeya 10y ago

Good luck getting funding for a Crispr startup.

jghn 10y ago
I'd imagine that they'd be willing to license the technology to a startup for a stake in the company or something like that.
- dekhn 10y ago
  The bar is pretty high for anybody who wants to make a product based on in-human CRISPR: https://www.broadinstitute.org/partnerships/office-strategic-alliances-and-partnering/information-about-licensing-crispr-genome-edi https://www.broadinstitute.org/partnerships/office-strategic... In short, if you want to sell a product, Editas gets right of first refusal to license from Broad, and only if they refuse would the startup be able to proceed to license. If you just want to use CRISPR for in house research, you have to license it; no idea if the fees are prohibitive.